Surrogacy in Ireland: Medical and Donor Requirements
The short answer: separate current law from future rules
As at 20 October 2026, Ireland has no operative comprehensive statutory scheme for surrogacy eligibility and approvals. The Health (Assisted Human Reproduction) Act 2024 was enacted, and the Assisted Human Reproduction Regulatory Authority (AHRRA) was established in October 2025, yet the official commencement table lists sections 6–119 as not yet in force. Those sections contain the Act’s main treatment, donor and surrogacy regime. [S1] [S10]
That does not mean that every medical or gamete-handling activity is unregulated. Irish rules on the quality and safety of human tissues and cells already regulate relevant reproductive cells, including donor selection and infection testing in specified circumstances. The key question is which rules apply to the particular clinic, gametes, storage and treatment pathway. Do not treat a provision enacted for the future as a current legal prohibition, and do not treat a clinic’s eligibility policy as legislation.
Which rules apply to gametes now?
The European Communities (Quality and Safety of Human Tissues and Cells) Regulations 2006 (S.I. No. 158/2006) define “reproductive cells” as cells intended for assisted reproduction. Their requirements address procurement, testing, handling, traceability and the work of tissue establishments. Schedule 3 sets selection and laboratory-testing criteria for reproductive-cell donors. The parallel EU technical rules distinguish direct-use partner donation from other donation pathways. [S2] [S9]
A further EU change is scheduled: most provisions of Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin (the SoHO Regulation) apply from 7 August 2027, when it also repeals Directive 2004/23/EC, subject to detailed transitional rules. If treatment, storage or import may cross that date, ask the establishment to confirm the applicable transition and authorisation requirements rather than assume today’s process will remain unchanged. [S13]
These are cell safety rules, not a complete surrogacy approval code. They do not themselves determine legal parentage, enforceability of a surrogacy agreement, passport rights or entry to another country.
The Children and Family Relationships Act 2015 separately regulates donor-assisted reproduction, including consent and donor information. The Department of Health says it applies to clinical procedures in Ireland where the woman giving birth is also the intending mother and the child is born in Ireland; it expressly excludes surrogacy. Do not automatically apply its parentage or National Donor-Conceived Person Register rules to a surrogacy case. [S3]
Donor assessment: medical history and interview
For a non-partner reproductive-cell donation under Schedule 3, selection must consider the donor’s age, health and medical history, gathered through a questionnaire and personal interview by a qualified, trained healthcare professional. The assessment must consider infection and other risks to the recipient and resulting child, as well as risks to the donor. For egg donation, the rule expressly notes ovarian stimulation, sedation and retrieval risks; psychological consequences may also matter. [S2]
Schedule 3 also requires, after the donor’s consent, genetic screening for autosomal-recessive genes known internationally to be prevalent in the donor’s ethnic background, plus an assessment of the risk of transmitting inherited conditions known in the family. The recipient must receive complete information about the risks and mitigation measures. The clinic should document the panel used and explain its relevance; the regulation does not prescribe one universal panel for every donor. [S11]
This is risk assessment, not a universal list of diagnoses that automatically disqualifies every donor or surrogate. Distinguish legal gamete screening from broader clinic criteria for the surrogate, intended parent or embryo-transfer recipient. Ask which rule applies to each person.
Infection screening for non-partner donors
Under Schedule 3, a reproductive-cell donation other than a partner donation must meet specified minimum laboratory criteria. The donor must test negative for HIV 1 and 2, hepatitis C (HCV), hepatitis B (HBV) and syphilis on a serum or plasma sample. A sperm donor must also test negative for chlamydia on a urine sample using a nucleic acid amplification test (NAT). These are not merely optional tests that a clinic may omit because it prefers a different commercial screening package. The applicable testing method and handling requirements must be checked against the current Irish regulations and the establishment’s procedures. [S2] [S9]
Request the screening report or written confirmation of required tests, dates, results, and any effect on gamete release or use. “Fully screened” is not a substitute for the actual test list and applicable legal pathway.
For non-partner sperm donations, the blood sample must be taken at donation and the sperm must be quarantined for at least 180 days. Repeat testing is normally required after that period. The rules remove the need for a repeat blood sample if the donation sample is additionally tested by NAT for HIV, HBV and HCV, or if processing uses a validated viral-inactivation step. These exceptions concern repeat testing; ask the clinic to document exactly which pathway applies. [S11]
HBV interpretation requires a scope check. Schedule 2 is expressly for donors other than reproductive-cell donors. Schedule 3 requires HBV testing for non-partner reproductive-cell donations by reference to Schedule 2 point 1.1, but does not expressly refer to point 1.3, which addresses anti-HBc-positive/HBsAg-negative results. Do not present that follow-up rule as definitively applicable to gamete donors without confirming the current consolidated text and its interpretation. For processed or stored partner donations, or donations resulting in embryo cryopreservation, Schedule 3 separately requires HBsAg and anti-HBc testing and states that positive results do not necessarily prevent partner donation under national rules. Ask the establishment to document the applicable pathway and clinical risk assessment before release or use. [S2]
Conditional tests and the partner-donation exception
Additional testing may be required depending on the donor’s history and the cells involved. The rules specifically mention HTLV-I antibody testing for donors who live in or come from high-prevalence areas, or whose sexual partners or parents come from such areas. Other tests may be appropriate in certain circumstances based on travel, exposure history and the type of cells, including RhD, malaria, cytomegalovirus (CMV) or Trypanosoma cruzi. The clinic should document why additional testing is or is not indicated for the case. [S2]
Important definition: the Regulations define “partner donation” as reproductive cells donated between a man and a woman who declare that they have an intimate physical relationship. Because this wording is specific, do not assume that the direct-use exemption automatically applies to a same-sex couple or another arrangement. Ask the tissue establishment to confirm the applicable category in writing and obtain Irish legal advice where needed. [S2]
Partner donation for direct use is treated differently: Schedule 3 selection criteria and laboratory tests need not be applied. For partner cells that are processed or stored, or lead to embryo cryopreservation, the clinician must document the justification and safety of the donation. Tests to assess cross-contamination include HIV 1/2, HBV markers HBsAg and anti-HBc, and HCV; HTLV-I or other tests may be required depending on risk. If HIV, HBV or HCV results are positive or unavailable, or the donor is known to pose an infection risk, separate storage is required. Positive results do not necessarily prevent partner donation. A narrow exception may apply to sperm processed for intrauterine insemination, not stored, where validated processes address cross-contamination and staff exposure. This is not a general exemption for any known donor or family member; ask the tissue establishment to classify the donation in writing.
The 2024 Act: enacted, but the main regime is not in force
The Health (Assisted Human Reproduction) Act 2024 contains detailed provisions for treatment providers, consent, counselling, embryo transfer, gamete donation, donor screening and domestic and international surrogacy. However, an Act’s enactment date is not the same as its commencement date. The official commencement table records commencement of Part 1 (with an exception) and parts of Part 9 on 13 October 2025, but lists sections 6–119 as not yet commenced. These include the central rules that would govern treatment and surrogacy. [S1] [S8]
AHRRA’s establishment does not prove the licensing and surrogacy-approval system is operational. Published provisions may remain uncommenced, so recheck status before relying on them.
Prospective medical and counselling criteria for a surrogate
As enacted, section 55 sets future domestic-surrogacy criteria: the woman must previously have given birth, be at least 25, receive a section 18 counselling report confirming suitability, and be approved by an appropriate medical specialist. Section 91 sets parallel criteria for permitted international surrogacy, requiring an AHR counsellor’s report and approval by a suitable specialist or equivalent practitioner in the foreign jurisdiction. [S6] [S7]
The Act also contains a restriction where a woman has acted as a surrogate on more than one previous occasion and achieved a clinical pregnancy on at least two occasions; the text defines clinical pregnancy by reference to a gestation of at least six weeks and an ultrasound-identified gestational sac. These are enacted provisions but, because the relevant sections are not yet commenced, they must be described as prospective rules, not current Irish eligibility requirements. A foreign country may have different current rules.
Prospective donor controls under the 2024 Act
Part 3 would create a broader framework for gamete and embryo donation, covering donor consent and screening, limits on use of one donor’s gametes or embryos, restrictions on certain genetically related gametes, and a ban on commercial payment for a relevant donation apart from permitted reasonable expenses. Section 33 includes a general limit intended to prevent one donation resulting in children being born into more than four families, subject to the Act’s detailed terms. [S8]
Do not present these as current Irish surrogacy rules: sections 6–119 remain uncommenced. Future operation may depend on regulations or amendments. For current cases, apply the rules governing the actual donation and the treatment-country law, while monitoring the 2024 Act.
What is law and what is clinic policy?
A clinic may set stricter medical thresholds for uterine and obstetric health, age, BMI, chronic conditions, medication, infection or genetic risk, mental health, smoking, substance use, ovarian stimulation and pregnancy. These may be clinically important, but a clinic protocol is not automatically a statutory prohibition.
Ask the provider to classify each requirement as (1) binding Irish/EU safety law, (2) law of the treatment country, (3) professional clinical guidance, or (4) its own policy. Obtain the written rule and the consequence of non-compliance; criteria may differ between clinics.
For Irish tissue handling, check the exact establishment and relevant activity against the HPRA’s current tissue-establishment list. A clinic or brand name does not prove every laboratory, storage or import activity is authorised. [S4] [S12]
Documents to obtain before agreeing to treatment
Before signing, paying a deposit or scheduling embryo transfer, request a written pack identifying the provider, gamete-handling establishment, legal basis and current authorisation. Ask for the donor-selection policy, medical questionnaire, test list and results, plus procedures for extra tests, positive findings, quarantine, release, traceability and disposal.
Request the surrogate’s eligibility protocol, final decision-maker, required obstetric records and any independent assessment required by law or clinic policy. Confirm consent forms, withdrawal process, donor data retained and later access rights. If a requirement is called “Irish law”, ask for the provision and commencement date.
Quick comparison: current rules and future provisions
| Issue | Position for a current decision | Practical response |
|---|---|---|
| Gamete handling and donor testing in Ireland | The 2006 tissue-and-cell rules are in force. | Identify the Schedule 3 category and obtain written test confirmation. |
| CFRA 2015 donor-assistance rules | The Department of Health says surrogacy is outside this framework. | Do not assume its parentage or register rules resolve a surrogacy case. |
| Surrogate age, prior birth and specialist approval under the 2024 Act | Sections 55 and 91 contain these criteria, but are not yet commenced. | Treat them as future law; separately check the treatment country. |
| Donor-family limits and other 2024 controls | Part 3 includes a four-family limit in section 33, but sections 6–119 are uncommenced. | Do not present these as current requirements; monitor commencement and regulations. |
| Clinic-specific eligibility criteria | May be required by the clinic but are not automatically law. | Get the written policy and distinguish law, guidance and practice. |
Practical sequence before embryo transfer
- Define the pathway. Record the treatment country, whether the surrogate uses her own egg or receives an embryo made from other gametes, and who supplies each sample.
- Verify the establishment. For handling in Ireland, check the relevant tissue establishment on the HPRA list and confirm that its authorisation covers that activity. For treatment abroad, verify the provider under that country’s regulator.
- Confirm screening. Obtain the donor category, history review, required infection tests, risk-based additional tests, results and storage/traceability procedures.
- Separate legal and clinical criteria. Get the medical/counselling requirements in writing, with the legal source, jurisdiction and any extra clinic policy.
- Check information and consent. Confirm recorded donor data, withdrawal rights and whether the child may later obtain identifying information under applicable law.
- Obtain cross-border advice. For a foreign programme used by an Irish resident, obtain separate advice on parentage, registration, citizenship and travel; a clinic’s “legal programme” label does not resolve these issues.
Keep dated copies of legislation, clinic policy, authorisations, screening confirmations and consents. Recheck commencement before treatment.
If the treatment or donor is abroad
The law of the clinic’s country governs many immediate questions about donor selection, testing, consent, storage and clinical eligibility. Do not assume Irish tissue-and-cell rules apply identically to every foreign clinic; foreign-law compliance does not itself settle Irish parentage, the child’s nationality or travel rights.
The 2024 Act contains future international-surrogacy rules, including section 91, but the official table reviewed lists the relevant sections as uncommenced. The Department of Health also expressly excludes surrogacy from the 2015 donor-assisted reproduction framework. [S7] [S3]
Before committing, ask lawyers in Ireland and the treatment country to confirm current rules, uncommenced Irish provisions and records needed later. Do not rely only on clinic or agency assurances.
Bottom line and limits of this guide
For current Irish surrogacy, the clearest established donor rules are the reproductive-cell safety requirements in S.I. No. 158/2006, including donor-history assessment and specified tests for non-partner donations. The 2015 donor-assisted reproduction framework does not itself govern surrogacy. The 2024 Act sets out future requirements, but sections 6–119 remain uncommenced in the table reviewed.
Do not guess which standards apply: obtain written confirmation of the donation category, legal basis, screening evidence, facility authorisation and clinic criteria, then verify Irish and treatment-country law.
Sources
- [S1] Health (Assisted Human Reproduction) Act 2024 — commencement table
- [S2] European Communities (Quality and Safety of Human Tissues and Cells) Regulations 2006 (S.I. No. 158/2006)
- [S3] Department of Health: Children and Family Relationships Act 2015
- [S4] HPRA: Tissue establishment list
- [S6] Health (Assisted Human Reproduction) Act 2024, section 55
- [S7] Health (Assisted Human Reproduction) Act 2024, section 91
- [S8] Health (Assisted Human Reproduction) Act 2024 — full text
- [S9] Commission Directive 2006/17/EC — technical requirements for human tissues and cells
- [S10] Department of Health: Minister establishes the Assisted Human Reproduction Regulatory Authority
- [S11] European Communities (Quality and Safety of Human Tissues and Cells) (Amendment) Regulations 2014 (S.I. No. 209/2014)
- [S12] European Communities (Quality and Safety of Human Tissues and Cells) (Amendment) Regulations 2019 (S.I. No. 33/2019)
- [S13] Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin (SoHO Regulation)
